RT Journal Article
SR Electronic
T1 Risk of diabetes and cardiovascular diseases in women with vaginal bleeding before 20 gestational weeks: Danish population-based cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.18.22272466
DO 10.1101/2022.03.18.22272466
A1 Elena Dudukina
A1 Erzsébet Horváth-Puhó
A1 Henrik Toft Sørensen
A1 Vera Ehrenstein
YR 2022
UL http://medrxiv.org/content/early/2022/11/28/2022.03.18.22272466.abstract
AB Importance The risk of cardiovascular outcomes following a pregnancy complicated by vaginal bleeding (VB) not ending in a miscarriage is not fully understood.Objective To study an association between pregnancy affected by VB and women’s subsequent risks of diabetes and cardiovascular outcomes.Design, Setting and Participants We conducted a population-based cohort study set in Denmark, 1994-2018. Using Danish nationwide registries, we identified 1,901,725 pregnancies among 903,327 women. Of these, 39,265 were affected by VB and ended in childbirth; 1,389,285 were unaffected by VB and ended in childbirth; 333,785 ended in termination, and 139,390 ended in a miscarriage.Exposure(s) Pregnancy affected by vaginal bleeding before 20 gestational weeks.Main outcome measures The outcomes were diabetes types 1 and 2, hypertension, ischaemic heart disease (including myocardial infarction), atrial fibrillation or flutter, heart failure, ischaemic and haemorrhagic stroke. We computed absolute risks and hazard ratios (aHRs) with robust 95% confidence intervals (CIs) adjusted for age, calendar year, reproductive history, comorbidities, and socioeconomic factors using Cox proportional hazards regression.Results At the end of the follow-up, among women with VB-affected vs VB-unaffected pregnancies, the cumulative risks of the outcome events were 1.7% vs 1.4% for diabetes type 1; 6.9% vs 5.6% for diabetes type 2; 11.1% vs 9.0% for hypertension; 3.6% vs 2.7% for ischaemic heart disease, including 1.1% vs 0.8% for myocardial infarction; 1.3% vs 1.0% for atrial fibrillation or flutter; 0.5% vs 0.5% for heart failure; 2.0% vs 1.3% for ischaemic stroke; and 0.8% vs 0.6% for haemorrhagic stroke and aHRs were 1.2 to 1.3-fold increased for diabetes types 1 and 2, hypertension, ischaemic heart disease, myocardial infarction, atrial fibrillation or flutter, and heart failure. The aHRs were 1.4 and 1.5-fold increased for ischaemic and haemorrhagic stroke, respectively. For comparisons of women with VB-affected pregnancy vs termination, aHRs were up to 1.3-fold increased for diabetes and hypertension. Analyses contrasting VB-affected pregnancy with miscarriage resulted in aHRs below or close to the null value.Conclusions Women’s risks of diabetes and cardiovascular outcomes were increased following VB-affected pregnancy when compared with VB-unaffected pregnancy or termination, but not when compared with miscarriage.Question Is having a pregnancy affected by vaginal bleeding and not ending in miscarriage associated with the increased risk of diabetes and cardiovascular outcomes in women?Findings This nationwide registry-based cohort study of 1,901,725 pregnancies among 903,327 women showed that in contrast with having a pregnancy without vaginal bleeding, having a pregnancy with vaginal bleeding before 20 gestational weeks was associated with woman’s increased risks of diabetes types 1 and 2, hypertension, ischaemic heart disease, including myocardial infarction, atrial fibrillation or flutter, heart failure, ischaemic and haemorrhagic stroke. The cardiovascular risks were increased when investigating a woman’s first pregnancy with vaginal bleeding before 20 gestational vs without vaginal bleeding during pregnancy; the associations remained when we additionally adjusted for smoking and body-mass index in a sensitivity analysis.Meaning The results of this study support current clinical practice on cardiovascular prevention in women with pregnancy complications and add to the body of evidence on a common pregnancy complication, vaginal bleeding, and its association with long-term risks of diabetes and cardiovascular conditions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDepartment of Clinical Epidemiology, Aarhus University partaking in studies with institutional funding from regulators and pharmaceutical companies, given as research grants to and administered by Aarhus University. None of these projects is related to the current study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No patient informed consent or ethical approval is required for registry-based research according to Danish legislation. The study was reported to the Danish Data Protection Agency (according to the Danish legislation) through registration at Aarhus University (record number: AU-2016-051-000001, sequential number 605).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is not available for sharing to protect the identity of participants according to Danish legislation.